Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s177. https://doi.org/10.25251/skin.7.supp.177